Compare ELME & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | ARDX |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2014 |
| Metric | ELME | ARDX |
|---|---|---|
| Price | $17.49 | $6.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $14.25 | $10.65 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $246,959,000.00 | ★ $398,234,000.00 |
| Revenue This Year | N/A | $22.77 |
| Revenue Next Year | N/A | $28.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.10 | ★ 58.12 |
| 52 Week Low | $13.95 | $3.21 |
| 52 Week High | $18.08 | $6.78 |
| Indicator | ELME | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 58.69 |
| Support Level | $17.36 | $5.69 |
| Resistance Level | $17.68 | $5.99 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 60.00 | 66.03 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.